EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D.

Company Announcement - EyePoint Pharmaceuticals appoints Dr Reginald J Sanders to its Board of Directors [1] - Dr Sanders is a distinguished leader in ophthalmology with extensive experience in retina research and business development [2] - Dr Sanders has served as President of the American Society of Retina Specialists and is a board member of Prism Vision Group [2] - Dr Sanders has over 50 publications and has been a principal investigator for landmark treatments like Lucentis [2] - Dr Sanders has received numerous honors including induction into the Retina Hall of Fame and the Packo Service Award [3] Clinical Development - EyePoint's lead product candidate DURAVYU is in Phase 3 global pivotal trials for wet AMD and Phase 2 trials for diabetic macular edema [4] - Topline data from the Phase 2 trial in diabetic macular edema is expected in Q1 2025 [4] - Topline data from both Phase 3 pivotal trials in wet AMD is expected in 2026 [4] - EyePoint's pipeline includes EYP-2301 a TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases [5] Technology and Partnerships - EyePoint leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery [4] - Vorolanib used in DURAVYU is licensed exclusively by Equinox Sciences for ophthalmic diseases outside of China Macao Hong Kong and Taiwan [6] - DURAVYU has been conditionally accepted by the FDA as the proprietary name for EYP-1901 [6]